Pathology & Histology Evaluation Service
Creative Biolabs provides high-fidelity biological validation essential for the transition from lead identification to therapeutic success. Our services enable the precise localization of novel biomarkers and the quantitative assessment of the tumor microenvironment (TME), ensuring your therapeutic candidate achieves the desired biological effect while maintaining a robust safety profile. By leveraging our multi-spectral imaging and automated scoring platforms, researchers can move beyond binary "positive/negative" results to understand the spatial "cross-talk" between immune cells and tumor architecture.
Introduction of Pathology and Histology Evaluation
Modern pathology has transitioned from a qualitative descriptive discipline into a quantitative, data-rich "spatial-omics" tool. Extensive evidence confirms that while manual histological estimation is highly subjective, AI-driven digital pathology can now accurately determine therapeutic response (pCR) by analyzing complex stromal biomarkers and immune "T-scores." Standardizing these evaluations, especially when monitoring for immune-mediated toxicities, is essential for the successful development and regulatory approval of next-generation biologics. Creative Biolabs remains at the forefront of this evolution, ensuring our clients have access to the most advanced diagnostic and analytical technologies available.
Comprehensive Pathological Solutions
Creative Biolabs offers an end-to-end suite of histological and pathological services designed to satisfy the rigorous data requirements of global regulatory bodies. Our portfolio spans from routine tissue preparation to advanced computational analyses.
Precision Immunohistochemistry (IHC) and Multiplex Immunofluorescence (mIF)
Our industry-leading staining solutions detect multiple phenotypic and functional markers simultaneously. By mapping PD-1/PD-L1 axis interactions alongside CD8+, FoxP3+, and CD68+ on a single section, we provide high-resolution immune landscape maps.
Molecular Pathology and Advanced In Situ Hybridization (ISH)
To correlate morphological findings with molecular drivers, we offer high-sensitivity ISH and FISH services. These visualize RNA and DNA expression within preserved tissue, verifying target engagement when protein expression is low.
Toxicologic Pathology and Safety Assessment
Our toxicologic pathology services evaluate tissue changes in preclinical models, ranging from acute to chronic studies. We identify drug-induced injury signals and provide GLP-compliant reports to ensure your data is robust.
Standardized Assessment of Immune-Related Adverse Events (irAEs)
Following international consensus guidelines, we provide standardized histological assessment of irAEs, including colitis and pneumonitis. Our pathologists accurately distinguish drug-induced architectural changes from underlying biological variations, ensuring precise safety margin monitoring.
Bridge the Gap from Bench to Bedside with Reliable Data — Inquire for a Customized Project Strategy
Workflow
Our streamlined workflow is designed to maximize data integrity and ensure rapid turnaround times.
Publication
This review examines pathology-based multiplex imaging techniques revolutionizing cancer immunotherapy assessment. It critically analyzes the limitations of conventional single-marker PD-L1 immunohistochemistry, including subjectivity and the inability to capture tumor-immune interactions. The authors comprehensively evaluate chromogenic, fluorescence, metal-based, and DNA-barcoding multiplex methods, highlighting their capacity for simultaneous multi-marker detection and spatial organization analysis. The integration of digital pathology and artificial intelligence for quantitative, reproducible biomarker assessment is discussed, emphasizing the potential of these approaches to improve patient stratification for immune checkpoint inhibitor therapy.
Fig.1 Principles of multiplex immunohistochemistry and immunofluorescence techniques. 1
Why Choose Us
Choosing Creative Biolabs means partnering with an industry leader dedicated to closing the "accuracy gap" in modern histology. While manual visual assessments of immune cell density are non-concordant with standardized results in 92% of cases, our AI-driven platforms provide reproducible, quantitative measurements for biomarkers like CD3+ and CD8+, eliminating subjectivity. We are pioneers in assessing irAEs, such as checkpoint-induced colitis, utilizing the latest international consensus guidelines for biopsy evaluation. Furthermore, our spatial intelligence goes beyond traditional pathology to map the exact relationships within the TME, offering critical data on how your drug influences immune recruitment and stromal remodeling.
Experience the Creative Biolabs Advantage in Digital Pathology — Request a Technical Quote Today
FAQs
Can you help with novel or non-standard biomarkers?
Yes. Creative Biolabs specializes in custom IHC/IF antibody optimization and protocol development for proprietary or emerging targets.
How is the accuracy of the AI analysis verified?
All AI-generated data undergoes a rigorous peer-review process by our board-certified pathologists to ensure biological accuracy and clinical relevance.
What are the advantages of multiplexing over serial sectioning?
Multiplexing preserves tissue architecture and allows for the analysis of cell-to-cell interactions on a single slide, which is not possible when markers are spread across multiple serial sections.
Customer Review
-
Unmatched Reproducibility
Using Creative Biolabs' digital immunoscoring in our research has significantly improved the reproducibility of our CD8+ density data across multiple trial sites, providing the statistical rigor we needed for our submission. - Dr. Al***son R -
Superior Spatial Analysis
The multiplex IF platform facilitated our understanding of FoxP3+ cell localization relative to the invasive margin, a critical spatial detail we had previously missed using standard IHC methods. - Prof. Ma***ew K
Related Services
Tissue Cross-Reactivity Evaluation Service
Creative Biolabs provides TCR studies via immunohistochemical assessment to identify non-target binding. We evaluate cross-reactivity to ensure immunological safety and support preclinical antibody development.
Learn More →Binding Affinity and Specificity Evaluation Service
Creative Biolabs provides ADEPT affinity and specificity assessments using SPR and ELISA. We evaluate binding kinetics, cross-reactivity, and molecular docking to optimize enzyme delivery and maximize drug accumulation in tumors.
Learn More →Contact Us
Creative Biolabs provides a sophisticated integration of classical histopathology, advanced multiplex imaging, and AI-driven spatial analysis. Our goal is to provide the scientific rigor and data clarity required to move your therapeutic candidate from the bench to the bedside. By addressing the inherent subjectivity of traditional pathology with objective, quantitative tools, we empower researchers to make more informed, data-driven decisions.
Partner with Our Experts to Redefine Your Tissue Analysis — Contact Our Team for a Detailed Consultation
Reference
- Kuczkiewicz-Siemion, O., et al. "The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy." Cancers (Basel) 14.15 (2022). Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers14153833
Download our brochure